List of Gralise drug patents

Gralise is owned by Almatica.

Gralise contains Gabapentin.

Gralise has a total of 5 drug patents out of which 4 drug patents have expired.

Expired drug patents of Gralise are:

  • US8192756
  • US8333992
  • US8252332
  • US7731989

Gralise was authorised for market use on 28 January, 2011.

Gralise is available in tablet;oral dosage forms.

Gralise can be used as treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia.

The generics of Gralise are possible to be released after 26 February, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192756 ALMATICA Gastric retained gabapentin dosage form
Oct, 2022

(3 months ago)

US8333992 ALMATICA Gastric retained gabapentin dosage form
Oct, 2022

(3 months ago)

US8252332 ALMATICA Gastric retained gabapentin dosage form
Oct, 2022

(3 months ago)

US7731989 ALMATICA Gastric retained gabapentin dosage form
Oct, 2022

(3 months ago)

US7438927 ALMATICA Methods of treatment using a gastric retained gabapentin dosage
Feb, 2024

(1 year, 22 days from now)

Drugs and Companies using GABAPENTIN ingredient

Market Authorisation Date: 28 January, 2011

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

How can I launch a generic of GRALISE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic